Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
H5N1 Influenza Vaccine · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Arm 1 | EXPERIMENTAL | 0.5mL of H5N1 vaccine 7.5ug |
| Arm 2 | ACTIVE_COMPARATOR | 0.25 or 0.5mL of H5N1 vaccine |
| Name | Type | Description |
|---|---|---|
| H5N1 influenza vaccine | BIOLOGICAL | One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen |
Inclusion Criteria: * Healthy subjects who previously participated in study V87P1, but did not receive the booster dose on day 202 Exclusion Criteria: * Pregnant or breastfeeding * Receipt of another vaccine or any investigational agent within the past 4 weeks * Surgery planned during the study p...
H5N1 Influenza Vaccine is used for prophylaxis of avian influenza, also known as bird flu, and for the prevention of avian influenza infection. It is an investigational vaccine being developed to protect against the H5N1 influenza virus strain.
H5N1 Influenza Vaccine is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The vaccine is currently in clinical development for the prevention of avian influenza.
H5N1 Influenza Vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and immunogenicity in various age groups.
H5N1 Influenza Vaccine has been studied in two completed Phase 2 clinical trials. NCT00537524 evaluated two doses of the vaccine in participants aged 6 months to 17 years in Finland, enrolling 471 participants. NCT00561184 assessed a booster dose in adults aged 18 years and older in Italy, enrolling 47 participants.
Yes, H5N1 Influenza Vaccine is classified as a monoclonal antibody modality. It is being developed as a vaccine for avian influenza prophylaxis, with clinical trials assessing its immunogenicity, safety, and tolerability in healthy volunteers.